FDA Brief

Warning letters Drugs

FDA warning letter to

Cergomex Imports, LLC

MediumIssued Aug 4, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

Cergomex Imports, an over-the-counter drug manufacturer, refused FDA records requests for its Sanetto Hands Sanitizer Gel.

What happened

FDA sent electronic requests for records on August 16 and August 31, 2022, to the email in Cergomex’s registration file, then called on October 24, 2022 and asked for a response by October 31, 2022. The firm did not answer the emails or phone contacts, and FDA’s August 1, 2023 phone attempts were unsuccessful. FDA said the firm refused to provide records and it had no indication of quality assurance for drugs registered as manufactured at the facility.

What FDA found

  1. The firm did not respond to FDA's August 16 and August 31, 2022 electronic requests for records about its drug manufacturing.

    FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)
  2. The firm refused to let FDA access or copy records, which the law treats as a prohibited act.

    FD&C Act section 301(e), 21 U.S.C. 331(e)
  3. The firm did not respond to FDA's October 24, 2022 phone request or later phone attempts, including on August 1, 2023.

  4. FDA had no indication of the level of quality assurance for drugs registered as manufactured at the firm's facility because the firm did not respond.

What FDA wants

FDA tells the firm to respond within 48 hours to confirm or update its registration and drug listing status and say whether it will provide the requested records; if it no longer makes drugs, it must delist all drugs and deregister the facility.

Who should pay attention

  • companies that buy or distribute hand sanitizer from Cergomex
  • OTC drug manufacturers with FDA registrations and listings
  • quality teams managing FDA records requests and registration status

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium